Substance / Medication

Scopolamine hydrobromide

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

12 trials linked to this intervention

12
Total Trials
1
Recruiting
6
With Results

Research Evidence

Published studies and systematic reviews

Sort:
[Efficacy of glycopyrronium bromide and scopolamine hydrobromide in patients with death rattle: a randomized controlled study].
Likar Rudolf, Rupacher Ernst, Kager Hans et al. · Wien Klin Wochenschr · 2008
PMID: 19116709RCT
Detection of Scopolamine Hydrobromide via Surface-enhanced Raman Spectroscopy.
Bao Lin, Sha Xuan-Yu, Zhao Hang et al. · Anal Sci · 2017
PMID: 29129861Other
Regulating effect of Qifu Yin on intestinal microbiota in mice with memory impairment induced by scopolamine hydrobromide.
Liu Shiqi, Zhang Qingling, Zhao Fuxia et al. · J Ethnopharmacol · 2024
PMID: 38851472Preclinical
Rodent models for dry eye syndrome: Standardization using benzalkonium chloride and scopolamine hydrobromide.
Chaudhari Pinal, Satarker Sairaj, Thomas Rinu et al. · Life Sci · 2023
PMID: 36731648Preclinical
[The protection of hydrogen-rich saline on a rat dry eye model induced by scopolamine hydrobromide].
Chu Y Y, Hua N, Ru Y S et al. · Zhonghua Yan Ke Za Zhi · 2017
PMID: 28494565Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Scopolamine hydrobromide (substance)
SNOMED CT
387477005
UMLS CUI
C0036444

Clinical Data

This intervention maps to 7 entities in the Healos knowledge graph.

7
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
12
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.